Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BCDA NASDAQ:GLMD NASDAQ:PHIO NASDAQ:SONN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCDABioCardia$2.13-0.5%$2.20$1.63▼$4.66$11.78M0.8183,023 shs15,173 shsGLMDGalmed Pharmaceuticals$1.55-4.9%$1.76$1.15▼$23.80$2.70M0.58384,370 shs238,205 shsPHIOPhio Pharmaceuticals$2.33-2.1%$2.36$0.97▼$9.79$11.42M0.862.66 million shs218,759 shsSONNSonnet BioTherapeutics$2.81-15.4%$3.01$1.08▼$19.30$10.51M1.035.00 million shs1.05 million shs7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCDABioCardia-0.47%-9.36%+2.40%-20.52%-29.24%GLMDGalmed Pharmaceuticals-4.91%-22.11%-14.36%+24.00%-57.98%PHIOPhio Pharmaceuticals-2.10%-14.96%-6.05%+18.88%-27.19%SONNSonnet BioTherapeutics-15.36%-29.57%-32.29%+106.62%-55.25%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBCDABioCardia2.7518 of 5 stars3.83.00.00.01.12.50.6GLMDGalmed Pharmaceuticals0.5113 of 5 stars0.02.00.00.00.62.50.6PHIOPhio Pharmaceuticals2.8669 of 5 stars3.53.00.00.02.32.50.6SONNSonnet BioTherapeutics2.1568 of 5 stars3.52.00.00.01.10.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCDABioCardia 3.50Strong Buy$25.001,073.71% UpsideGLMDGalmed Pharmaceuticals 2.00HoldN/AN/APHIOPhio Pharmaceuticals 3.00Buy$14.00500.86% UpsideSONNSonnet BioTherapeutics 3.00Buy$20.00611.74% UpsideCurrent Analyst Ratings BreakdownLatest GLMD, PHIO, BCDA, and SONN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/25/2025PHIOPhio PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.006/5/2025PHIOPhio PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$14.00(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCDABioCardia$60K195.25N/AN/A$0.18 per share11.83GLMDGalmed PharmaceuticalsN/AN/AN/AN/A$9.87 per shareN/APHIOPhio PharmaceuticalsN/AN/AN/AN/A$0.69 per shareN/ASONNSonnet BioTherapeutics$20K445.39N/AN/A($0.71) per share-3.96Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCDABioCardia-$7.95M-$2.33N/AN/AN/AN/A-30,792.60%-223.06%8/12/2025 (Estimated)GLMDGalmed Pharmaceuticals-$7.52M-$16.66N/A∞N/AN/A-32.21%-28.59%8/27/2025 (Estimated)PHIOPhio Pharmaceuticals-$7.15M-$6.42N/A0.62N/AN/A-105.65%-89.19%8/13/2025 (Estimated)SONNSonnet BioTherapeutics-$7.44MN/A0.00∞N/AN/A-777.92%-271.32%8/13/2025 (Estimated)Latest GLMD, PHIO, BCDA, and SONN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025N/APHIOPhio Pharmaceuticals-$0.36N/AN/AN/AN/AN/A8/13/2025Q3 2025SONNSonnet BioTherapeutics-$0.49N/AN/AN/AN/AN/A5/22/2025Q1 2025GLMDGalmed PharmaceuticalsN/A-$0.62N/A-$0.62N/AN/A5/14/2025Q1 2025BCDABioCardia-$0.39-$0.59-$0.20-$0.59N/AN/A5/13/2025Q2 2025SONNSonnet BioTherapeutics-$0.92-$0.89+$0.03-$0.89N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBCDABioCardiaN/AN/AN/AN/AN/AGLMDGalmed PharmaceuticalsN/AN/AN/AN/AN/APHIOPhio PharmaceuticalsN/AN/AN/AN/AN/ASONNSonnet BioTherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCDABioCardiaN/A0.360.36GLMDGalmed PharmaceuticalsN/A9.029.02PHIOPhio PharmaceuticalsN/A10.5810.58SONNSonnet BioTherapeuticsN/A1.031.03Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCDABioCardia20.57%GLMDGalmed Pharmaceuticals76.14%PHIOPhio Pharmaceuticals57.31%SONNSonnet BioTherapeutics9.45%Insider OwnershipCompanyInsider OwnershipBCDABioCardia20.00%GLMDGalmed Pharmaceuticals19.80%PHIOPhio Pharmaceuticals0.59%SONNSonnet BioTherapeutics2.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCDABioCardia405.50 million4.40 millionOptionableGLMDGalmed Pharmaceuticals201.65 million1.33 millionNot OptionablePHIOPhio Pharmaceuticals104.80 million4.77 millionNot OptionableSONNSonnet BioTherapeutics103.17 million3.10 millionNot OptionableGLMD, PHIO, BCDA, and SONN HeadlinesRecent News About These CompaniesSonnet BioTherapeutics Appoints Interim CEO Raghu RaoAugust 1 at 5:30 PM | tipranks.comSolana-based treasury model goes global as DeFi Development launches franchiseJuly 17, 2025 | msn.comWLFI tokens to become tradable after World Liberty holders’ voteJuly 17, 2025 | msn.comHyperliquid Strategies Inc. plan for $583M treasury boosts HYPE priceJuly 16, 2025 | cointelegraph.comSonnet BioTherapeutics Merges in $888M Deal to Launch Hyperliquid Strategies and HYPE TreasuryJuly 15, 2025 | thecurrencyanalytics.comTSonnet BioTherapeutics Stock Jumps 82% After Deal With Rorschach I: Retail Stays ExuberantJuly 15, 2025 | msn.comPublic Firm Sonnet BioTherapeutics to Launch HyperLiquid Treasury in New DealJuly 14, 2025 | coinspeaker.comSonnet BioTherapeutics Shares Climb After Plan to Transfer Into Public Crypto Treasury Co.July 14, 2025 | marketwatch.comWhy did Sonnet BioTherapeutics (SONN) Shares Gain over 200% in Premarket Trading?July 14, 2025 | tokenist.comTHyperliquid Price Forecast: HYPE eyes gains following Sonnet BioTherapeutics' rebrandJuly 14, 2025 | fxstreet.comHYPE coin price up 200%, Sonnet BioTherapeutics merges into Hyperliquid StrategiesJuly 14, 2025 | msn.comMassive deal sends biotech stock rallying 367%July 14, 2025 | msn.com$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Sonnet BioTherapeutics, Inc. (NASDAQ: SONN)July 14, 2025 | globenewswire.comWhy Is Sonnet BioTherapeutics Stock Trading Higher On Monday?July 14, 2025 | benzinga.comSONN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Sonnet BioTherapeutics, Inc. Is Fair to ShareholdersJuly 14, 2025 | businesswire.comThis stock rockets 260% after $900 million mega crypto dealJuly 14, 2025 | finbold.comFSonnet BioTherapeutics, Inc. Announces $888 Million Business Combination to Launch a HYPE Cryptocurrency Treasury Reserve StrategyJuly 14, 2025 | globenewswire.comSonnet BioTherapeutics Completes $2 Million Convertible Notes SaleJuly 2, 2025 | tipranks.comsonnet biotherapeutics receives nasdaq delisting noticeJune 4, 2025 | investing.comSonnet Chief Medical Officer, Richard Kenney, M.D., to Present at the 6th Annual Cytokine-Based Drug Development SummitMay 1, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGLMD, PHIO, BCDA, and SONN Company DescriptionsBioCardia NASDAQ:BCDA$2.13 -0.01 (-0.47%) Closing price 08/1/2025 03:59 PM EasternExtended Trading$2.14 +0.01 (+0.47%) As of 08/1/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California.Galmed Pharmaceuticals NASDAQ:GLMD$1.55 -0.08 (-4.91%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.53 -0.02 (-1.29%) As of 08/1/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.Phio Pharmaceuticals NASDAQ:PHIO$2.33 -0.05 (-2.10%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$2.32 -0.01 (-0.60%) As of 08/1/2025 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors. It is also developing PH-894, an INTASYL compound in IND enabling studies to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, effecting the immune system and the tumor. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is based in Marlborough, Massachusetts.Sonnet BioTherapeutics NASDAQ:SONN$2.81 -0.51 (-15.36%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$2.79 -0.02 (-0.68%) As of 08/1/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sonnet BioTherapeutics Holdings, Inc., a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead product candidate is SON-1010, a fully human single-chain version of interleukin 12 that is in Phase 1b/2a clinical trial for the treatment of solid tumor indications, including ovarian cancer, non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6, which is in Phase 1b/I2a clinical trail to treat chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy; and SON-1210, a bispecific compound for solid tumor indications, including colorectal cancer. It has a license agreement with New Life Therapeutics Pte, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin-6; and strategic development collaboration with Sarcoma Oncology Center to advance SON-1210. The company is headquartered in Princeton, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale AbbVie Stock Eyes Breakout as Pipeline and Profits Grow Why Bloom Energy Stock Could Break to New Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
